SCAD and Pregnancy: The Heart Attack New Mothers Are Not Warned About

The chest pain a woman feels three weeks after giving birth is too often filed under exhaustion. Sometimes it is her coronary artery tearing. The clinical error is not one of knowledge, exactly; it is one of instinct: the postpartum patient is not the patient cardiologists are trained to pattern-match to, and that mismatch costs lives.

The Mechanism

Spontaneous coronary artery dissection is not atherosclerosis. There is no plaque. There is no lipid core rupturing into the lumen. What happens instead is a tear in the coronary arterial wall itself, specifically in or near the intima or the outer medial layers, that allows blood to enter the wall and form an intramural hematoma. That hematoma has nowhere to go except to expand within the arterial wall, compressing the true lumen from outside. The result is the same as any coronary obstruction: diminished or absent blood flow to myocardium, ischemia, and, depending on the degree of occlusion and the time to recognition, infarction.

The false lumen created by the intramural hematoma is not a thrombus. It does not respond the same way to antiplatelet therapy. Stenting it does not fix it in the way stenting an atherosclerotic occlusion can fix that. Advancing a wire into a dissected coronary runs the genuine risk of entering the false lumen and extending the dissection rather than restoring flow.

Pregnancy creates conditions that make this arterial wall tear more likely through at least three intersecting mechanisms.

Hemodynamic loading across the full gestational period. Cardiac output increases by 30 to 50 percent during pregnancy (Sanghavi and Rutherford, Circulation 2014). Heart rate rises by 15 to 20 beats per minute. Blood volume expands by approximately 40 to 50 percent. These changes are sustained across months, not hours. The shear stress on coronary arterial walls over a 40-week pregnancy is substantially elevated compared to baseline. A wall with underlying structural vulnerability (whether from fibromuscular dysplasia, connective tissue disorder, or idiopathic arterial fragility) is being stressed continuously.

Hormonal effects on arterial wall architecture. Elevated progesterone during pregnancy has been associated with reduced synthesis of collagen and elastin in arterial walls. Histopathological analysis of aortic tissue from women who died peripartum demonstrates fragmentation of elastic and collagen fibers, mucoid accumulation, and loss of smooth muscle cells in the medial layer (Manalo-Estrella and Barker, Archives of Pathology 1967; Immer et al., European Journal of Cardiothoracic Surgery 2003). Whether the same process occurs in the smaller coronary arteries has not been definitively established at the level of randomized evidence, but the structural parallel is biologically plausible and consistent with clinical observation. 4 / Promising

Delivery itself as an acute precipitant. Active labor and the pushing phase of delivery involve sustained Valsalva-maneuver physiology: prolonged increases in intrathoracic and intra-abdominal pressure that translate into acute surges in coronary artery intraluminal pressure. A coronary wall that has undergone months of hemodynamic and hormonal stress is meeting its most acute mechanical challenge at the moment of delivery. Multiple case series have documented SCAD occurring during or within hours of active labor, with the left anterior descending artery the most commonly involved vessel.

Postpartum hormonal withdrawal. The rapid decline in estrogen and progesterone after delivery is one of the most abrupt endocrine transitions in human physiology. The relationship between this transition and the postpartum vulnerability window for SCAD is clinically observed in registry data (the majority of P-SCAD events cluster in the first two to four weeks after delivery) but the precise molecular mechanism linking hormonal withdrawal to arterial wall fragility in the immediate postpartum period remains under active investigation. 4 / Promising What is not speculative is the timing: the postpartum window is when the risk materializes.

What the Evidence Shows

The foundational evidence base for pregnancy-associated SCAD comes from several overlapping sources: multicenter SCAD registries, the Mayo Clinic SCAD cohort, case series from centers with SCAD expertise, and the 2018 AHA Scientific Statement on SCAD authored by Hayes et al. (Circulation 2018). These do not constitute randomized trial evidence (SCAD is too rare and too heterogeneous for that level of evidence to exist), but the registry data are consistent across sites and years. 4 / Promising

Prevalence in peripartum MI. Among all causes of myocardial infarction in women of childbearing age, SCAD is disproportionately represented in the peripartum period. Registry analyses estimate that 20 to 25 percent of all SCAD events occur in the peripartum window, defined variably as the third trimester through the first year postpartum. A population-based analysis by Saw et al. (Journal of the American College of Cardiology 2014) and subsequent registry reports have consistently placed pregnancy-associated SCAD as one of the two leading causes of MI in pregnant and postpartum women, alongside postpartum cardiomyopathy, though the timing of these two diagnoses differs in ways that matter clinically.

The severity gradient. Data from Elkayam and colleagues’ peripartum cardiac registry, as well as from the AHA Scientific Statement, document that P-SCAD presents with greater severity than non-pregnancy SCAD on multiple dimensions. Multivessel involvement is more frequent. Left main coronary artery dissection, which is among the most hemodynamically threatening SCAD presentations, is over-represented in the peripartum population compared to the overall SCAD registry. In-hospital mortality in P-SCAD series is higher than in non-pregnancy SCAD, reflecting both the severity of presentation and the challenges of managing dissection in a postpartum patient who may have had recent delivery and whose hemodynamic reserve is variable. Rates of requiring mechanical circulatory support, urgent PCI, or emergency coronary artery bypass grafting are elevated in the peripartum subset.

Angiographic recognition. SCAD does not look like atherosclerotic coronary disease on angiography. The classic patterns are a spiral or linear radiolucent flap visible within the vessel, abrupt lumen narrowing without an identifiable atheromatous lesion, haziness of the vessel wall, or a long smooth stenosis inconsistent with focal plaque. In practice, angiographers who have not seen many SCAD cases can misinterpret these findings. The false lumen may not be visible at all if the intramural hematoma is large enough to compress the true lumen to a slit without leaving visible dissection planes. Optical coherence tomography (OCT), when available and when the patient’s hemodynamic status permits, provides wall-level resolution that characterizes the dissection anatomy before any decision about wire placement is made. The 2018 AHA SCAD Statement specifically endorses OCT for angiographic characterization in stable SCAD presentations. 4 / Promising

Timing versus postpartum cardiomyopathy. Both SCAD and postpartum cardiomyopathy (PPCM) cause cardiac dysfunction in postpartum women, and both present with dyspnea and reduced exercise tolerance. The distinction matters because the management is entirely different. PPCM typically presents in the last month of pregnancy or the first five months postpartum, most commonly after the first week, with a dilated cardiomyopathy pattern on imaging and normal or near-normal coronary anatomy. P-SCAD presents with an acute ischemic pattern: ST changes, regional wall motion abnormality, elevated troponin, and an angiographic finding in the coronary artery rather than diffuse ventricular dysfunction. P-SCAD clustering is heaviest in the first two to four weeks postpartum; presentations in the second through fifth postpartum month are more likely to be PPCM. Both diagnoses require exclusion of pulmonary embolism and aortic dissection before settling on either.

The FMD connection. Fibromuscular dysplasia (FMD) is a non-atherosclerotic, non-inflammatory arterial disease characterized by abnormal fibromuscular growth in arterial walls, most commonly manifesting in the renal and carotid arteries. It is over-represented in SCAD patients across the registry literature; estimates of FMD prevalence among SCAD patients range from 50 to 86 percent in different series (Hayes et al., Circulation 2018). FMD is itself a systemic arterial condition, and its presence in the renal or cervicocephalic arteries in a SCAD patient implies a generalized arterial fragility. Every SCAD patient requires vascular imaging of additional arterial beds, including the renal arteries, iliac arteries, and cervicocephalic arteries, to characterize the extent of FMD involvement. This matters for prognostication, for risk counseling regarding future pregnancy, and because FMD itself has its own surveillance and management implications.

Recurrence Risk and Long-Term Follow-Up: What the Registry Data Show

SCAD is not a one-time event for all patients who survive it. Long-term follow-up data from the Vancouver SCAD cohort published by Saw and colleagues and from registries at multiple centers have documented recurrence rates of 15 to 30 percent over 5 to 10 years of follow-up. The heterogeneity of these estimates reflects differences in patient selection, follow-up duration, and the criteria used to define recurrence: some registries count only angiographically confirmed new dissections, while others include troponin-positive events with imaging consistent with new ischemia.

The predictors of recurrence that appear across multiple registry analyses are: fibromuscular dysplasia confirmed on vascular imaging (patients with FMD have higher recurrence rates than those without), younger age at first event, emotional stress as the precipitant of the index event, and ongoing hormonal exposures including oral contraceptives. Pregnancy-associated SCAD specifically carries a distinct recurrence risk profile because the hormonal and hemodynamic conditions that contributed to the first dissection — elevated progesterone, increased cardiac output, mechanical arterial wall stress — are reproducible in a subsequent pregnancy. The individualized assessment of these factors requires a center with documented SCAD experience, because the recurrence risk calculation is not generalizable across all SCAD subtypes.

For the management period after an acute SCAD event, beta-blockers have been recommended by the 2018 AHA SCAD Scientific Statement and the 2022 ESC MINOCA guideline based on the mechanistic rationale that sympathetic activation contributes to intimal tear propagation and may be a trigger for recurrence. This recommendation is grounded in observational registry data and mechanistic reasoning, not randomized trial evidence; no RCT on beta-blocker therapy post-SCAD exists, and one is unlikely to be conducted given the rarity of the disease. Dual antiplatelet therapy duration decisions after SCAD are also less established than in atherosclerotic MI, and most centers use shorter courses to avoid anticoagulation-related hematoma expansion risk in the acute setting.

Coronary imaging follow-up at four to eight weeks — typically by CTA or repeat invasive angiography — documents healing and establishes the baseline needed before any high-hemodynamic-stress decision is made. The most consequential such decision is a subsequent pregnancy. A SCAD survivor who becomes pregnant without documented coronary healing and without individualized risk assessment from a SCAD-experienced center is proceeding without the information her case requires. This is not a theoretical concern: the registry data on subsequent pregnancy after SCAD, while limited in sample size, document maternal cardiac events including recurrent SCAD in a subset of women whose coronary status before the subsequent pregnancy was not fully characterized. 3 / Early

What to Do This Week

These steps apply depending on where you are in this picture.

1. If you had unexplained chest pain, jaw pain, left arm pressure, or sudden profound dyspnea during pregnancy or in the first year postpartum and it was attributed to a non-cardiac cause without ECG and troponin evaluation, request a cardiology referral now. A SCAD event that appeared to resolve may have caused myocardial damage that was not characterized. A chest pain episode in the postpartum period that was attributed to anxiety, musculoskeletal strain, or dehydration without objective cardiac testing is an evaluation gap that should be closed, not accepted.

2. If you are a SCAD survivor considering future pregnancy, seek evaluation specifically at a center with documented SCAD experience before making that decision. The relevant questions (coronary healing documented on imaging, FMD characterization across all vascular beds, residual myocardial function, and individualized recurrence risk assessment) cannot be answered adequately in a general cardiology clinic that manages two or three SCAD cases per year. Ask directly whether your cardiologist has managed P-SCAD cases or collaborates with a maternal-fetal medicine team for high-risk cardiac pregnancies.

3. If you are a clinician seeing a postpartum patient with chest symptoms, ECG and troponin before reassurance, not after. The peripartum differential that must be excluded includes pulmonary embolism, aortic dissection, SCAD, and postpartum cardiomyopathy. None of these can be safely ruled out by clinical impression. The history of recent delivery does not lower the pre-test probability of serious pathology; in the case of SCAD, it raises it.

4. If an acute MI is confirmed in a peripartum patient and catheterization is planned, notify the interventional team before the procedure that SCAD must be excluded before wire placement. If the facility does not have SCAD-experienced operators or OCT capability, document the conversation about transfer. This is not excessive caution; it is the appropriate standard given what is known about the consequences of misidentifying SCAD as atherosclerotic disease on the table.

5. If you are a SCAD survivor at any stage, confirm that FMD screening of renal and cervicocephalic arteries has been performed. FMD is a systemic arterial disease, and its characterization affects counseling on future pregnancy risk, blood pressure management, and surveillance intervals. If your initial workup did not include cross-sectional vascular imaging beyond the coronary arteries, this is a gap in your longitudinal care.

Chest pain in the weeks after delivery does not belong in a category labeled “probably nothing.” It belongs in a category labeled “uncharacterized until proven benign.” That is a different starting point, and in a woman three weeks postpartum with a tearing sensation in her chest and a rising troponin, it is the only defensible one.

Related reading

For the foundational SCAD mechanism and non-pregnancy population: SCAD: The Heart Attack That Tears the Artery Wall.

For the FMD screening that every SCAD diagnosis requires: The SCAD-FMD Connection.

For the broader postpartum cardiac picture in the first year: The Cardiac Year After Delivery.